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SUPPLEMENTARY MATERIAL 
 
Research participants  
The DIAGRAM stage 1 analyses comprised a total of 26,676 T2D cases and 132,532 control participants 
from 18 GWAS. The Metabochip stage 2 follow up comprised 16 studies (D2D2007, DANISH, DIAGEN, 
DILGOM, DRsEXTRA, EMIL-Ulm, FUSION2, NHR, IMPROVE, InterACT-CMC, Leipzig, METSIM, 
HUNT/TROMSO, SCARFSHEEP, STR, Warren2/58BC) with Metabochip data (1), in which the 
participants did not overlap those included in stage 1. Stage 1 study sizes ranged between 80 and 7,249 T2D 
cases and from 455 to 83,049 controls. The study characteristics are described in detail in Supplementary 
Table 1. The Metabochip follow-up study sizes ranged from 101 and 3,553 T2D cases and from 586 to 6,603 
controls. Details of Metabochip replication cohorts have been described in detail previously (1,2). For SNVs 
not captured on Metabochip directly or by proxy, we performed follow-up in 2,796 individuals with T2D and 
4,601 controls from the EPIC-InterAct study (3). In addition, we used 9,747 T2D cases and 61,857 controls 
from the GERA study (4) to follow-up six low frequency variants not captured on Metabochip. All study 
participants were of European ancestry and were from the United States and Europe. All studies were 
approved by local research ethic committees, and all participants gave written informed consent. 
Overview of Study Design and Analysis Strategy 
We performed inverse-variance weighted fixed-effect meta-analyses of 18 stage 1 GWAS (Supplementary 
Table 1). Following imputation to the 1000G multi-ethnic reference panel, each study performed T2D 
association analysis using logistic regression, adjusting for age, sex, and study-specific covariates, under an 
additive genetic model. Fifteen of the 18 studies repeated analyses also adjusting for body mass index (BMI). 
A total of 40 loci reached genome-wide significance (p=5x10
-8
) in the stage 1 meta-analysis, of which four 
mapped >500kb from previously-known T2D-associated loci, and were therefore considered likely to 
represent novel signals. At a lesser level of significance (p<10
-5
), we identified 48 additional putative novel 
signals. In stage 1, we identified fifty-two regions in which the most strongly associated SNP had a p<10
-5
, 
was greater than 500kb distant from the nearest known T2D associated variant and was in r
2
 <.02 with all 
known T2D associated variants. Of the combined set of 52 putative novel signals, 46 featured a lead SNV 
with MAF >5%. From each of these 52 regions, we selected the most strongly-associated variant for follow-
up in stage 2. As the stage 1 meta-analysis had exhausted most European-ancestry studies with available 
GWAS data, stage 2 was primarily based on 16 independent European-ancestry studies (2) genotyped on the 
Metabochip custom array (5). Of the 52 putative lead variants from stage 1, 29 variants or their LD proxies 
(r
2≥0.6) were present in MetaboChip. Specifically, four SNVs were themselves present on the Metabochip, 
20 were represented by a proxy (r
2
>0.8) and an additional 5 by a proxy in lower linkage disequilibrium (LD) 
(0.8>r
2
>0.6) (Table 1, Supplementary Table 6, Supplementary Figure 1A-C). Novel loci were defined 
using the threshold for genome-wide significance in the combined stage 1 and stage 2 meta-analysis or in 
stage 1 alone, when no suitable proxy was available. The remaining 23 variants were followed-up in EPIC-
InterAct study. We neither observed any additional signals attaining genome-wide significance threshold, 
nor detected any nominally significant effects in this follow-up stage alone. Six low-frequency variants were 
followed-up additionally in the GERA study (Supplementary Table 6). 
Genotyping, imputation and quality control 
Genotyping of individual stage 1 studies was carried out using commercial genome-wide single-nucleotide 
variant (SNV) arrays as detailed in Supplementary Table 1. We excluded samples and SNPs as described in 
Supplementary Table 1. We imputed autosomal and X chromosome SNVs using the all ancestries 1000 
Genomes Project (1000G) reference panel (1,092 individuals from Africa, Asia, Europe, and the Americas, 
(March, 2012 release)) using miniMAC (6) or IMPUTE2 (7). EPIC-InterAct was genotyped on the Illumina 
HumanCoreExome chip and imputed using the 1000G reference panel (March, 2012 release). The 
imputation parameters are given in Supplementary Table 1. Insertion/deletion variants were not analysed 
due to the lower quality of their calls in the 1000G reference panel release used as compared to later panel 
releases. After imputation, from each study we removed monomorphic imputed variants or those with study-
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specific imputation quality r
2
-hat<0.3 (miniMAC) or proper-info<0.4 (IMPUTE2, SNPTEST). Metabochip 
studies were imputed using with the same 1000G panel (1,2) as used in Stage 1. 
To compare the variant imputation quality and distribution of minor allele frequency (MAF) for variants 
imputed using the 1000G March 2012 reference panel to those imputed using the HapMap2 reference panel 
European individuals, we also imputed into the WTCCC sample using HapMap2 reference panel European 
individuals. We independently binned the SNVs from the two imputation panels by allele frequency and 
computed the per-bin SNP number and the average proper_info score. 
Statistical analyses 
In stage 1, in each study we performed logistic regression association analysis of T2D with genotype dosage 
using an additive genetic model including as covariates age, sex and principal components derived from the 
genetic data to account for population stratification. We further applied genomic control (GC) correction to 
study-level association summary statistics to correct for residual population structure not accounted for by 
principal components adjustment. We combined the association results using inverse variance-weighted 
fixed effect meta-analysis using both GWAMA (8) and METAL (9) , and observed identical results. The 
stage 1 meta-analysis had 11.7M autosomal and 260k chromosome X SNVs that 1) had a total minor allele 
count >5 and 2) were present in ≥3 studies. The lambda (GC) value was 1.08, while inflation estimates from 
LDscore regression (10) showed no evidence of population stratification suggesting lambda (GC)=1. We 
performed inverse variance weighted fixed-effects meta-analysis of the 16 stage 2 Metabochip studies 
(lambda GC correction applied based on QT-interval variant set (1)) and the 18 stage 1 studies using 
GWAMA (8) and METAL (9) software. Heterogeneity was assessed using the I
2
 index from the complete 
study-level meta-analysis. We combined stage 1 and stage 2 results by inverse variance-weighted fixed-
effect meta-analysis. 
We performed a secondary T2D association analysis by modelling body mass index (BMI) as covariate in 15 
studies (not including DGDG, GoDARTS and WTCCC). The total sample size for this analysis was 21,440 
T2D cases and 97,052 controls, (Neff=70,242). The lambda (GC) was 1.05. Genetic effect sizes (beta 
coefficients) estimated from models with and without BMI adjustments were compared using a matched 
analysis within the same subset of 15 studies:  
(𝛽𝑛𝑜𝐵𝑀𝐼−𝛽𝐵𝑀𝐼)
√𝑆𝐸(𝛽𝑛𝑜𝐵𝑀𝐼)2+𝑆𝐸(𝛽𝐵𝑀𝐼)2−2𝜌×𝑆𝐸(𝛽𝑛𝑜𝐵𝑀𝐼)×𝑆𝐸(𝛽𝐵𝑀𝐼)
 , where 𝛽𝐵𝑀𝐼 
and 𝛽𝑛𝑜𝐵𝑀𝐼 are the estimated genetic effect from models with and without BMI adjustment, 𝑆𝐸(𝛽) is the 
estimated standard error of the estimates, and  is the estimated correlation between 𝛽𝐵𝑀𝐼 and 𝛽𝑛𝑜𝐵𝑀𝐼 
obtained from all genetic variants (=0.90). 
Comparison between HapMap and 1000G reference variant sets  
We made LocusZoom(11) regional plots of the Stage 1 meta-analysis results indexed by lead SNV for the 13 
novel loci, and estimated LD using the EUR 1000G March 2012 variant set (Supplementary Figure 2). We 
also made regional plots indexed by the lead 1000G SNV, but otherwise only including SNVs present in the 
previous HapMap2-imputed analyses(1,12). 
Power calculations  
We performed power calculations
10
 over a range of odds ratios (ORs), using the corresponding genotype 
relative risk (GRR) in the power calculation, to (i) determine the effect size that would yield 80% power 
based on a grid search and (ii) to provide power estimates for pre-specified ORs, for specified risk allele 
frequency (RAF). The RAF is defined as the frequency of the allele that increases T2D risk in the stage 1 
meta-analysis. We determined power as a function of the GRR, RAF, alpha=5×10
-8
, and the average 
weighted effective case sample size, assuming a 1:1 ratio of cases and controls. For each variant, we defined 
weighted effective case sample size as the product of the variant-specific effective case sample size and the 
average variant-specific imputation quality (based on r
2
 hat or info measures available from each included 
study). To calculate the average weighted effective case sample size, for each RAF we selected the 10,000 
stage 1 meta-analysis variants with RAF closest to the target RAF (taking equal proportions of variants 
above and below the RAF), and took the average of the 10,000 weighted effective case sample sizes. 
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Approximate conditional analysis with GCTA  
To identify if multiple statistically independent signals were present in known and novel T2D associated 
regions, we performed approximate conditional analysis in the stage 1 sample using GCTA (v1.24) (13). 
Among 70 established T2D-associated and 13 novel loci (p<5×10
-4
), we analysed SNVs in the 1Mb-window 
around each lead variant, conditioning on the lead SNV at each locus. We ran the GCTA analysis using three 
separate genotype reference panels for estimation of LD between variants (14): UK10K project (N=3,621), 
Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS (15)) study (3,298 T2D cases and 
3,708 controls) and Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS (16)) study 
(n=949). We considered loci as containing distinct signals (in the initial and further rounds of analysis) if a 
SNV reached locus-wide significance after accounting for region-specific multiple testing (p<10
-5
) in all 
three reference panels. Where we observed distinct signals, we then conditioned on the original lead SNV, 
and the newly observed distinct SNV(s) to detect further signals, until no additional signal was identified at 
p<10
-5
. We identified six regions with more than one independent signal (18 distinct signals). In each region 
with multiple signals, for each independent variant we conditioned on all other independent variants in the 
region and used these results were used for finemapping (below). At KCNQ1, we performed conditioning 
using GCTA model selection which better handles the large number of independent signals (using the 
UK10K reference panel).  
Finemapping analyses using credible set mapping 
The goal of finemapping was to identify sets of 99% credible causal variants for the lead independent 
variants at known and novel loci. We used credible set fine-mapping (17) within 95 distinct signals (at 82 
loci) with T2D-association signals p<5x10
-4
 in the present stage 1 to investigate whether 1000G-imputation 
allowed us to better resolve the specific variants driving these associations (Supplementary Tables 3 and 
9). We included in the credible set analysis all signals where the lead independent SNV reached p<5x10
-4
 in 
the stage 1 meta-analysis, as SNVs with weak association, mostly those identified in non-European GWASs, 
generally yield very large credible SNP sets. In regions with multiple independent variants, we used the 
signal remaining following approximate conditional analysis on all other independent variants in the region 
(see above). To define the locus boundaries, for each lead SNV we identified the outermost variants from the 
set of variants in r
2
 ≥ .2 with the lead SNV and added an additional flanking region of .02 cM to each side. 
To perform credible set mapping, the T2D stage 1 meta-analysis results were converted to Bayes’ factors 
(BF) for each variant within the variant/locus boundary (17). The posterior probability that SNVj was causal 
was defined by:  
𝜑𝑗 =  
𝐵𝐹𝑗
∑ 𝐵𝐹𝑘𝑘
 
where, BFj denotes the BF for the jth SNV, and the denominator is the sum of all included BFs. A 99% 
credible set of variants was created by ranking the posterior probabilities from highest to lowest and 
summing them until the cumulative posterior probability exceeded 0.99. To estimate the credible set sizes we 
would have observed with HapMap imputation-based meta-analysis results, we recomputed the posterior 
probabilities after first restricting to variants observed in previous HapMap-imputed analyses.  
T1D/T2D discrimination analysis 
Given the overlap between loci previously associated with T1D and the newly associated T2D loci, we used 
an inverse variance weighted Mendelian randomisation approach (18) to test whether this was likely to 
reflect misclassification of T1D cases as individuals with T2D in the current study. Briefly, using 50 SNVs 
associated with T1D at genome-wide significance (19), we tested the association of genetic predisposition to 
T1D with T2D in the present analysis. If some proportion of T2D cases in the current study actually are T1D, 
we would expect that the T1D risk variants to consistently predict T2D risk. We performed analysis with and 
without the lead SNVs showing associations with both T1D and T2D (p<0.05 for T2D).  
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Expression quantitative trait loci (eQTL) analysis 
Lead SNVs at all 13 novel loci mapped to non-coding sequence, leaving uncertain the identities of the 
effector transcripts through which the T2D-risk effects are mediated. To highlight potential effectors, we first 
considered RNA expression data, focusing on data from pancreatic islets, adipose, muscle, liver, and whole 
blood, and seeking coincidence (r
2
>0.8) between the lead T2D-associated SNVs and drivers of regional cis-
eQTLs (p<5x10
-6
) (Supplementary Table 10). To look for potential biological overlap of T2D lead variants 
and eQTL variants, we extracted the lead (most significantly associated) eQTL for each tested gene from 
existing datasets for pancreatic islets (20), skeletal muscle (21,22), adipose tissue(22–26), liver (22,24,27–
30) and whole blood (which has the largest sample size of available eQTL studies) (22,23,26,31–47) . 
Additional eQTL data was integrated from online sources including ScanDB 
(http://www.scandb.org/newinterface/about.html), the Broad Institute GTEx Portal 
(http://www.gtexportal.org/home/), and the Pritchard Lab (eqtl.uchicago.edu). Additional liver eQTL data 
was downloaded from ScanDB and cis-eQTLs were limited to those with p<10
-6
.We considered that a lead 
T2D SNV showed potential evidence of influencing gene expression if it was in high LD (r
2
>0.8) with the 
lead eQTL SNP, and if the lead eQTL SNP had p< 5 x 10
-6
   
Hierarchical clustering of T2D-related metabolic phenotypes 
Starting with the T2D associated SNV variants in the finemapping set, we identified sets of variants with 
similar patterns of T2D related quantitative trait association. For the T2D associated SNVs, we obtained 
T2D-related quantitative trait z scores from published HapMap-based GWAS meta-analysis for: fasting 
glucose (FG (48)), fasting insulin adjusted for BMI (FIadjBMI (48)), homeostasis model assessment for 
beta-cell function (HOMA-B (48)), homeostasis model assessment for insulin resistance (HOMA-IR (48)), 
2-h glucose adjusted for BMI (2hGluadjBMI (49)), proinsulin (PR (50)), corrected insulin response (CIR 
(51)), body mass index (52), high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), total 
cholesterol (TC), triglycerides (TG), all from the Global Lipids Genetics Consortium (53). When the result 
for a SNV was not available, we used the results from the variant in highest r
2
 (r
2
>0.6). We coded the z-
scores such that a positive sign indicated that the trait value was higher for the T2D risk allele, a negative 
sign that the trait value was lower for the T2D risk allele. We performed complete linkage hierarchical 
clustering and used the Euclidian distance dissimilarity measure L
2
=15% as a threshold to define the loci 
clusters. We tested the validity of groups through multi-scale bootstrap resampling with 50,000 bootstrap 
replicates, as described previously(54). All distances, clustering analyses and statistical calculations were 
done using stats, gplots, pvclust, fpc and vegan packages in the R programming language (R Core Team 
(2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. URL http://www.R-project.org/).  
Functional annotation and enrichment analysis  
We tested for enrichment of genomic and epigenomic annotations obtained from two sources. First, we 
obtained chromatin states for 93 cell types (after excluding cancer cell lines) from the NIH Epigenome 
Roadmap project. For each cell type, we collapsed active enhancer (EnhA) and promoter (TssA) states into 
one annotation for that cell type. Secondly, we obtained binding sites for 165 transcription factors (TF) from 
ENCODE (55) and Pasquali et al. (56). We first sought to extend these analyses to the denser variant 
coverage and expanded number of GWAS signals in the present meta-analysis (Supplementary Table 9). 
Across credible sets for the 95 distinct signals with p<5x10
-4
 in the present stage 1 European analysis 
(Supplementary Tables 3 and 9), we used a fractional logistic regression model to compare a binary 
indicator of variants overlapping a total of 261 functional annotations to the posterior probabilities for 
association derived from the fine-mapping analysis (πc) (Supplementary Table 12). For each TF, we 
collapsed all binding sites into one annotation. We then tested for the effect of variants with each cell type 
and TF annotation on the variant posterior probabilities (πc) using all variants in the 95 credible regions (ie 
100% credible sets). We used a generalized linear model where the dependent variable is πc value for each 
variant and the predictor variable is a binary indicator of overlap of the variant and the annotation, a (1 if 
yes, 0 if no). We included several additional binary indicators for generic gene-based annotations in the 
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model for each annotation - 3UTR (u), 5UTR (v), coding exon (c), and within 1kb upstream of GENCODE 
Tss (t) - as well as a categorical variable for locus membership (l). 
log (
π𝑐
1 − π𝑐
) =  𝛽0 + 𝛽1𝑎 +  𝛽2𝑢 + 𝛽3𝑣 + 𝛽4𝑐 +  𝛽5𝑡 +  𝛽6𝑙  , π𝑐  ~ 𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 
For each annotation, we obtained the estimated effect size and standard error from this model. We then re-
calculated the standard error using the sandwich variance estimator (R package sandwich). We calculated a 
z-score by dividing the effect size by the re-estimated standard error, and calculated a two-sided p-value 
from the z-score. We also applied this model to the three subsets of loci visually identified from the 
hierarchical clustering as having similar T2D-related trait association patterns. In each analysis, we 
considered an annotation significant if it reached a Bonferroni-corrected p-value threshold of 2x10
-4 
(.05/256 
annotations).  
Pathway analyses with DEPICT 
We used the Data-driven Expression Prioritized Integration for Complex Traits (DEPICT) tool (57) to i) 
prioritize genes that may represent promising candidates for T2D pathophysiology, and (ii) identify 
reconstituted gene sets that are enriched in genes from associated regions and might be related to T2D 
biological pathways. As input we used independent SNVs (LD-pruning parameters: r
2
<0.05 in the 1000 
Genomes project phase 1 reference panel including 268 unrelated individuals from CEU, GBR and TSI 
populations; release date 2011-05-21; physical distance threshold=500kb) selected from the set including 
stage1 meta-analysis SNVs with p<10
-5
 and lead variants at established loci. We then used the DEPICT 
method (57) to construct associated regions by mapping genes to independently associated SNVs, if they 
overlapped or resided within LD window (r
2
 >.0.5) with the independently associated SNV. Variants within 
the major histocompatibility complex region (chromosome 6, base pairs 25,000,000 through 35,000,000) 
were excluded. This gave 206 independent regions covering 328 genes for the analysis with DEPICT.  For 
the calculation of empirical enrichment p values, we used 200 sets of SNVs randomly drawn from entire 
genome within regions matching by gene density; we performed 20 replications for FDR estimation. For 
each significantly enriched reconstituted gene set, we plotted the five genes that most strongly mapped to the 
given gene sets and resided within an associated T2D locus. The mapping strength between a gene and a 
reconstituted gene set was denoted by a Z-score shown in parenthesis after the gene identifier in 
Supplementary Table 10. After the gene set enrichment analysis, we omitted reconstituted gene sets for 
which genes in the original gene set were not nominally enriched (Wilcoxon rank-sum test). By design, 
genes in the original gene set are expected to be enriched in the reconstituted gene set; lack of enrichment 
complicates interpretation of the reconstituted gene set because the label of the reconstituted gene set will be 
inaccurate. Using this procedure the “Megacephaly” reconstituted gene set was removed from the results. To 
visualize the 20 reconstituted gene sets with p<10
-5
 in Cytoscape (58) (Supplementary Figure 10), we 
estimated their overlap by computing the pairwise Pearson correlation coefficient r between each pair of 
gene sets followed by discretization into one of three bins; 0.3≤ρ<0.5 as low overlap, 0.5≤ρ<0.7 as medium 
overlap, and ρ≥0.7 as high overlap. 
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1. QQ- and Manhattan plots of the discovery association meta-analysis results. 
A) QQ-plot of all the signals. B) QQ-plot of previously established signals. C) QQ-plot of novel signals. D) 
Manhattan plot. Signals of association reaching genome-wide significance for the first time in the present 
study (p<5x10
-8
) are colored in red; blue dots represent previously established loci (Supplementary Table 
3). The Y-axis was trimmed at –log10(p-value)=40 for easier visualisation; the TCF7L2 association signal 
(p=1.35×10
-81
) falls far beyond this range (Supplementary Table 3).  
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Supplementary Figure 2. Regional plots for the thirteen novel T2D loci. In the left panel, the plot is 
based using all 1000 Genomes March 2012 multi-ethnic SNV set, whereas in the right panel the plot is 
restricted to SNVs present in HapMap CEU reference set. 
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Supplementary Figure 3. QQ-plot of the expected vs. observed P-values for heterogeneity between 
BMI-adjusted and unadjusted association analysis models for established and novel T2D loci. The 
FTO, TCF7L2, MC4R and SLC30A8 loci show large differences between models (pheterogeneity=5.70x10
-29
, 
3.51x10
-13
,  5.54x10
-6 
and 6.94x10
-5
, respectively). 
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Supplementary Figure 4. Regional plots for T2D loci showing additional distinct signals (p<10
-5
) in the 
approximate conditional analysis. First, unconditional analysis results are shown, followed by results 
conditioned on the lead SNV and other distinct signals. In the last plot for each locus the results for lead 
SNV conditional on the distinct signal(s) are shown. 
21 
 
 
 
Supplementary Figure 5. Forest plots of the A) putative low frequency distinct signal (rs188827514) 
and B) previously established (Steinthorsdottir et al.) low-frequency variant (rs76895963) at CCND2 for 
their associations with T2D. Odds ratios (OR) with their 95% confidence intervals (CI) are shown from 
unconditioned models. 
22 
 
 
 
 
Supplementary Figure6. Regional architecture of TP53INP1 locus. In the right panel the figure is plotted 
using all 1000 Genomes SNVs and highlights the new lead SNV (rs11786613) independent from the 
previous lead variant, signal visible in the left panel the plot is restricted to SNVs present in HapMap. 
 
 
 
Supplementary Figure 7. Association of variation in GLP2R with T2D after approximate conditional 
analyses on either A) the lead SNV (rs78761021), or B) D470N.  
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Supplementary Figure 8. Effects on T2D of 50 established T1D variants. All effects are aligned to T1D 
risk-raising allele. Loci are sorted from top to bottom by the magnitude of association with T1D.  
24 
 
 
Supplementary Figure 9. Significantly enriched reconstituted gene sets by DEPICT. We report 20 
significantly enriched reconstituted gene sets (FDR<0.05, Supplementary Table 11). Reconstituted gene 
sets are represented by nodes and their overlap by edges. Reconstituted gene sets are colour-coded based on 
their degree of enrichment in genes at the associated T2D loci (darker means more significant). DEPICT 
identified 21 significantly enriched reconstituted gene sets; one gene set was omitted due to a potential 
mismatch between the reconstituted gene set identifier and the reconstituted gene set (see Methods). For each 
gene set, the three genes exhibiting the highest likelihood within the given gene set and being within 
associated T2D loci are shown. Pairwise overlap between reconstituted gene sets were estimated by 
computing the Pearson correlation coefficient r between two reconstituted gene sets followed by 
discretization into one of three bins; 0.3≤ r <0.5 denotes low overlap, 0.5≤ r <0.7 denotes medium overlap, 
and r≥0.7 denotes high overlap. Edges representing overlap corresponding to r <0.3 are not shown. 
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Supplementary Figure 10. Type 2 diabetes credible sets are enriched for genomic annotations. We 
calculated the posterior probability of causality for all variants at 95 established T2D loci. We then tested the 
effect of variants annotated with protein-coding genes, cell type chromatin state, and transcription factor 
binding on the posterior probabilities across all loci. We identified significant effects among coding exons 
and pancreatic islet chromatin, and for binding sites of the FOXA2, NKX2.2, PDX1, and EZH2 transcription 
factors.  
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Supplementary Figure 11. Genomic annotation at credible sets of novel loci. A) The T2D signal at the 
BCAR1 locus contains a variant rs8056814 with a 57% probability of being causal for the signal. This variant 
overlaps an enhancer active in pancreatic islets proximal to the CTRB1 gene. B) The novel T2D signal at the 
CMIP locus is also associated with BMI and lipid phenotypes. The variant rs2925979 has a 91% probability 
of being causal for the CMIP signal and overlaps an enhancer active in liver, which is the most enriched cell 
type in the BMI/lipid physiology group.  
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BIOLOGY BOX  
 
ACSL1: chr4:185708807 (rs60780116) is an intronic variant in acyl-CoA synthetase long chain family 
member 1 coding gene (ACSL1), an isozyme that converts free long-chain fatty acids into fatty acyl-CoA 
esters, playing a key role in lipid biosynthesis and fatty acid degradation. ACSL1 is highly expressed in 
adipose, liver, skeletal muscle tissue and in whole blood, but expressed at lower levels in pancreas(1). Recent 
reports have implicated ACSL1 in regulating systemic glucose homeostasis(2), potentially via an effect on 
metabolic flexibility and capacity to switch between fatty acid and glucose metabolism. Variants in ACSL1 
have previously been associated with Kawasaki disease(3) (r
2
=0.12).    
HLA-DQA1:  Variation in the HLA region has been strongly associated with T1D(4) (r
2
=0.08) and other 
autoimmune diseases, including multiple sclerosis(5) (r
2
=0.47) and inflammatory bowel disease(6) (r
2
=0.13). 
Associations with total cholesterol and LDL cholesterol have also been reported(7) (r
2
=0.06). The lead SNV 
for T2D association in the HLA region (chr6:32594309; rs9271774) lies ~2kb upstream of HLA-DQA1. It is 
in high LD (r
2
=0.82) with a SNV strongly associated with expression of HLA-DRB5 in pancreatic islets(8). 
Analyses (see main text) suggest that the T2D association is not the result of misclassification of individuals 
with T1D as T2D cases in the present study.  
SLC35D3: Index variant chr6:137287702 (rs6918311) is located ~20kb downstream of the RNA gene 
NHEG1 (neuroblastoma highly expressed 1), which has no well characterized function. Also proximal to the 
lead SNV are: (1) SLC35D3, which is a member of the solute carrier family 35 and a regulator of the 
biosynthesis of platelet-dense granules with possible role in carbohydrate transport; (2) PEX7,  (peroxisomal 
biogenesis factor 7) encoding for the cytosolic receptor for the set of peroxisomal matrix enzymes, which is 
involved in cell metabolism and is associated with peroxisome biogenesis disorders and implicated in 
autism; and (3) IL20RA, which encodes for a subunit of the receptor for interleukin 20, and is a cytokine 
suggested to be involved in epidermal function. 
MNX1: chr7:157027753 (rs1182436) is an intronic variant in UBE3C, which encodes for a ubiquitin protein 
ligase. The lead SNV in the locus lies ~100kb upstream of MNX1, which is highly expressed in pancreas(1)  
containing coding mutations recently implicated in neonatal diabetes(9).  
ABO: chr9:136155000 (rs635634) variant lies ~5kb upstream of ABO gene, which determines blood group 
by modifying the oligosaccharides on cell surface glycoproteins. Variation in or near ABO has been 
associated with a very wide range of phenotypes, including glycaemic(10), lipid traits (7) (r
2
=1), coronary 
artery disease(11) and stroke(12) (r
2
=0.83). The lead variant at this locus is in low LD (r
2
<0.05) with blood 
group-defining markers(13).  
PLEKHA1: chr10:124186714 (rs2292626) is an intronic variant in PLEKHA1 (pleckstrin homology domain 
containing, family A member 1). The encoded protein localises to the plasma membrane where it specifically 
binds phosphatidylinositol 3,4-bisphosphate. This protein may be involved in the formation of signalling 
complexes in the plasma membrane. Variants in modest LD (rs10490924; r
2
=0.27) have been associated with 
age-related macular degeneration(14). 
 
HSD17B12: chr11:43877934 is a 3’UTR variant of HSD17B12 encoding the enzyme 17-beta 
hydroxysteroid dehydrogenase-12.  HSD17B12 encodes 17beta-hydroxysteroid dehydrogenase, involved in 
fatty acid metabolism(15) and estrogen sex steroid hormone formation. HSD17B12 has been identified as 
central to adipocyte differentiation(16), and a correlated variant (rs2176598; r
2
=0.68) was recently associated 
with BMI(17). However, rs1061810 remained associated with T2D after adjustment for BMI, and we found 
only a nominal difference in the association of rs1061810 with T2D in meta-analyses with or without 
adjustment for BMI (Supplementary Table 4), potentially indicating a role for HSD17B12 in risk of 
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diabetes independently of associations with adiposity. Other associations from this locus have been reported 
with forced vital capacity(18) (r
2
=0.59) and neuroblastoma(19) (r
2
=0.24).  
MAP3K11: chr11:65364385 (rs111669836) is located next to KCNK7 (potassium channel, subfamily K, 
member 7) gene, a member of the superfamily of potassium channel proteins. MAP3K11 encodes the 
Mitogen-activated protein kinase 11, part of the serine/threonine kinase family. MAP3K11 has been 
implicated in regulation  of pancreatic beta-cell death(20). Variation at this locus has previously been 
associated with e.g. height(21) (r
2
=0.02)  and lipid levels(7) (r
2
=0.08). 
NRXN3: chr14:79945162 (rs10146997) is an established variant associated with waist circumference(22), 
BMI(23)  and obesity(24). It is an intronic variant in the NRXN3 (Homo sapiens neurexin 3) gene, which is 
part of a family of central nervous adhesion molecules It is expressed in the same sub-cortical regions where 
reward training neuronal pathways are expressed. 
CMIP: chr16:81534790 (rs2925979). This gene encodes a c-Maf inducing protein that plays a role in the T-
cell signalling pathway. C-mip down-regulates NF-κB activity and promotes apoptosis in podocytes(25)  in 
cases of idiopathic nephrotic syndrome (INS). Associations with WHR(26), adiponectin(27)  and HDL 
cholesterol(7) levels have been reported for this same variant. 
ZZEF1: chr17:4014384 (rs7224685) is an intronic variant in the ZZEF1 (zinc finger, ZZ-type with EF-hand 
domain 1) gene related to calcium ion binding. This locus was previously implicated in functional 
impairment in major depressive disorder, bipolar disorder and schizophrenia(28).  
GLP2R: chr17:9780387 (rs78761021) is an intronic variant in the glucagon-like peptide 2 receptor (GLP2R) 
gene belonging to a G protein-coupled receptor superfamily. It is closely related to the glucagon receptor 
(GCGR) and GLP1R. Glucagon-like peptide-2 (GLP2) is a 33-amino acid proglucagon-derived peptide 
produced by intestinal enteroendocrine cells.  
GIP: the nearest gene to the detected signal (chr17:46967038, rs12941263) in this region is ATP5G1, coding 
for a subunit of mitochondrial ATP synthase and involved in “energy production”, in lipid transports and in 
cellular metabolism. Another gene within locus, GIP encodes an incretin hormone that belongs to the 
glucagon superfamily and is gastric inhibitory polypeptide. GIP is a potent stimulator of insulin secretion 
from pancreatic beta-cells following food ingestion and nutrient absorption via its G protein-coupled receptor 
activation of adenylyl cyclase and other signal transduction pathways(29). Variants (rs46522, rs318095) in 
high LD (r
2
=0.97) with our identified SNV at GIP have been associated with susceptibility to coronary heart 
disease(11) and  height(30). Variation in the receptor for GIP (GIPR) have previously been associated with 
glycemic traits and T2D(31,32). 
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